8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 27, 2015 (May 20, 2015)

ACELITY L.P. INC.

(Exact name of registrant as specified in its charter)

Guernsey	333-184233-14	98-1022387
(State or other jurisdiction of incorporation or organization)	Commission File Number	(I.R.S. Employer Identification No.)

12930 West Interstate 10, San Antonio, Texas	78249
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (210) 524-9000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The governing board of directors (the “Board”) of Acelity L.P. Inc. (the “Company”) are the directors of Chiron Holdings GP, Inc., the general partner of Chiron Guernsey Holdings L.P. Inc., which is the parent of the Company.

On May 20, 2015 the Board appointed Kevin Buehler and Alex Décary to the Board. Mr. Buehler will serve on the Compliance Committee of the Board and Mr. Décary will serve on each of the Audit Committee, Compliance Committee and Executive Committee of the Board.

In connection with these appointments, the Company and certain of its subsidiaries and each of Mr. Buehler and Mr. Décary will enter into the Company’s standard indemnification agreement for directors, the form of which was filed with the SEC on January 23, 2013 as Exhibit 10.1 to Amendment No. 3 to Kinetic Concepts, Inc. Registration Statement on Form S-4.

For further details on this announcement, please see attached the press release filed as Exhibit 99.1 to this Current Report.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated May 27, 2015, issued by Acelity L.P. Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ACELITY L.P. INC. (REGISTRANT)
Date: May 27, 2015	By:	/s/ John T. Bibb
	Name:	John T. Bibb
	Title:	Authorized Signatory

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated May 27, 2015, issued by Acelity L.P. Inc.

EX-99.1

News Release

For more information, contact:

Cheston Turbyfill	Caleb Moore
Acelity Corporate Communications	Acelity Investor Relations
Phone: +1 210-515-7757	Phone: +1 210-255-6433
Email: cheston.turbyfill@acelity.com	Email: caleb.moore@acelity.com

Acelity L.P. Inc. Appoints Two New Members to its Board of Directors

San Antonio, May 27, 2015 – Acelity L.P. Inc., a global wound care and regenerative medicine company, today announced the addition of Kevin J. Buehler and Alexandre Décary to its Board of Directors, effective May 20, 2015. Kevin and Alexandre bring tremendous business acumen and unique expertise that will strengthen Acelity’s presence on a global scale.

“Kevin and Alexandre bring strong experiences in both global business and finance that will add unique and valuable perspectives to Acelity’s Board,” said Joe Woody, President and CEO of Acelity. “Kevin brings extensive management experience in the healthcare industry and Alexandre has a tremendous financial and corporate leadership background; collectively, their counsel will help to guide Acelity’s growth as a global leader in wound care and regenerative medicine.”

Kevin has more than 30 years of experience in the healthcare and consumer industries, with knowledge of U.S. and international operations. He has a distinguished career, most recently serving as the Division Head of Alcon Laboratories, Inc., a division of Novartis from April 2011 to May 2014. Kevin has held a variety of leadership positions within the Alcon Laboratories organization, including: Senior Vice President of Global Markets, Chief Marketing Officer, and President and CEO of Alcon, Inc. Kevin served on the Board of Directors for Alcon prior to the merger with Novartis. He holds a BA from Carroll College in Waukesha, Wis., with concentrations in business administration and political science. He is a graduate of the Harvard Program for Management Development.

Alexandre brings strong business, financial and accounting experience to Acelity. Currently, Alexandre serves as senior director, private equity, at PSP Investments, where he is responsible for leading direct investments in various sectors. Prior to joining PSP Investments in 2015, he was Vice President, mergers and acquisitions, at Aimia Inc., a data-driven marketing and loyalty analytics company where he was responsible for the company's growth through strategic investments and acquisitions in the G20. From 2004 to 2012, Alexandre worked at RBC Capital Markets in the investment banking group where he had coverage responsibility for Canadian companies across various sectors. He began his career at Ernst & Young LLP in the audit and corporate finance departments. Alexandre completed a bachelor’s degree in Business Administration and a Graduate Diploma in Public Accountancy degree from HEC Montréal, as well as a Masters in Finance degree from the London Business School. He holds the CPA (Canada) and CFA designations.

About Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people’s lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit acelity.com.

###